(Q33595073)

English

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

Adrian Trenholme

2

object named as

Adrian Trenholme

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

author name string

Pilar Fernández

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Katia Abarca

3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

M Pamela Griffin

4

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Micki Hultquist

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Brian Harris

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Genevieve A Losonsky

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Motavizumab Study Group

8

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

publication date

3 June 2010

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

38

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

https://scigraph.springernature.com/pub.10.1186/1471-2431-10-38

0 references

From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898783

14 July 2018

Motavizumab, a neutralizing anti-Respiratory Syncytial Virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898783

14 July 2018

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898783

14 July 2018

Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898783

14 July 2018

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898783

14 July 2018

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898783

14 July 2018

Risk of primary infection and reinfection with respiratory syncytial virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898783

14 July 2018

Respiratory syncytial virus infection in children with bronchopulmonary dysplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898783

14 July 2018

From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898783

14 July 2018

Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases

1 reference

https://api.crossref.org/works/10.1186%2F1471-2431-10-38

21 January 2018

Joint policy statement--guidelines for care of children in the emergency department

1 reference

https://api.crossref.org/works/10.1186%2F1471-2431-10-38

21 January 2018

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

1 reference

https://api.crossref.org/works/10.1186%2F1471-2431-10-38

21 January 2018

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants

1 reference

https://api.crossref.org/works/10.1186%2F1471-2431-10-38

21 January 2018

Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children

1 reference

https://api.crossref.org/works/10.1186%2F1471-2431-10-38

21 January 2018

Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children

1 reference

https://api.crossref.org/works/10.1186%2F1471-2431-10-38

21 January 2018

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

1 reference

https://api.crossref.org/works/10.1186%2F1471-2431-10-38

21 January 2018

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2431-10-38

21 January 2018

Respiratory syncytial viral infection in infants with congenital heart disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20525274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20525274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2431-10-38

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Dimensions Publication ID

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2431-10-38

9 September 2019

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33595073&oldid=2178747747"